Editorial Commentary
The characteristics and prognostic role of thymic epithelial tumors with paraneoplastic autoimmune syndromes
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S321-S322
.
(31 December 2019)
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S323-S326
.
(31 December 2019)
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S327-S330
.
(31 December 2019)
Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S331-S333
.
(31 December 2019)
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S334-S338
.
(31 December 2019)
Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S339-S342
.
(31 December 2019)
Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S343-S346
.
(31 December 2019)
Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S347-S350
.
(31 December 2019)
Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S351-S354
.
(31 December 2019)
Improving outcomes for brain metastases in EGFR mutated NSCLC
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S355-S359
.
(31 December 2019)
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S360-S363
.
(31 December 2019)
Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S364-S368
.
(31 December 2019)
Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S369-S372
.
(31 December 2019)
Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S373-S377
.
(31 December 2019)
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S378-S382
.
(31 December 2019)
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S383-S386
.
(31 December 2019)
Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S387-S390
.
(31 December 2019)
Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S391-S394
.
(31 December 2019)
For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S395-S399
.
(31 December 2019)
The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S400-S402
.
(31 December 2019)
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S403-S406
.
(31 December 2019)
Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S407-S411
.
(31 December 2019)
The natural course of incidentally detected, small, subsolid lung nodules—is follow-up needed beyond current guideline recommendations?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S412-S417
.
(31 December 2019)
Optimal management of pulmonary ground-glass opacity nodules
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S418-S424
.
(31 December 2019)
Ground glass nodules with 5 years’ stability can grow after 10-year follow-up: do genetic features determine the fate?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S425-S427
.
(31 December 2019)
Surveillance of ground glass nodules—when is enough, enough?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S428-S429
.
(31 December 2019)
Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S430-S434
.
(31 December 2019)
Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S435-S438
.
(31 December 2019)
Spread through air spaces in lung neuroendocrine tumor
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S439-S442
.
(31 December 2019)
Lung neuroendocrine tumors: a new addition to the evolving list of spread through air spaces
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S443-S446
.
(31 December 2019)
Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what’s known and what’s next
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S447-S450
.
(31 December 2019)
ERAS in VATS—do we really need to follow the trend?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S451-S453
.
(31 December 2019)
Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S454-S459
.
(31 December 2019)
Text-mining in cancer research may help identify effective treatments
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S460-S463
.
(31 December 2019)
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S464-S467
.
(31 December 2019)
Importance of semaphorins in cancer immunity
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S468-S470
.
(31 December 2019)
Letter to the Editor
Awareness: potential toxicities of carbon nanotubes
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S471-S472
.
(31 December 2019)
News
Application of the CARE guideline as reporting standard in the Translational Lung Cancer Research
Translational Lung Cancer Research
2019;
8
(Suppl 4)
:S473
.
(31 December 2019)
